My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Exelixis, Inc. - Common Stock (NQ:EXEL)

42.14 -0.51 (-1.20%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm

September 02, 2025

From The Schall Law Firm

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

September 02, 2025

From Pomerantz LLP

Via GlobeNewswire

Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development

August 29, 2025

From Exelixis, Inc.

Via Business Wire

Is the Market Bullish or Bearish on Exelixis? ↗

August 26, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

August 29, 2025

From Pomerantz LLP

Via GlobeNewswire

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September

August 27, 2025

From Exelixis, Inc.

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

August 25, 2025

From Pomerantz LLP

Via GlobeNewswire

EXELIXIS INC (NASDAQ:EXEL) Emerges as a Compelling Value Investment Opportunity ↗

August 25, 2025

Exelixis (EXEL) is a strong value investing candidate, trading below intrinsic value with a solid financial profile, high profitability, and strong growth prospects.

Via Chartmill

EXELIXIS INC (NASDAQ:EXEL) Emerges as a Top Growth at a Reasonable Price (GARP) Stock ↗

August 22, 2025

EXELIXIS INC (EXEL) is a top GARP stock with strong growth, high profitability, and a reasonable valuation, making it a compelling investment opportunity.

Via Chartmill

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

August 21, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

August 17, 2025

From Pomerantz LLP

Via GlobeNewswire

Exelixis Inc (NASDAQ:EXEL): A Strong Growth Stock with Bullish Technical Setup ↗

August 16, 2025

Exelixis (EXEL) is a strong growth stock with solid fundamentals—17.5% revenue growth, high profitability, and no debt—plus a bullish technical setup, signaling a potential breakout opportunity.

Via Chartmill

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

August 13, 2025

From Pomerantz LLP

Via GlobeNewswire

The Analyst Verdict: Exelixis In The Eyes Of 19 Experts ↗

August 12, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exelixis, Inc. - EXEL

August 09, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

August 05, 2025

From Pomerantz LLP

Via GlobeNewswire

Exelixis EXEL Q2 2025 Earnings Call Transcript ↗

August 04, 2025

Via The Motley Fool

Topics Earnings

Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week (July 28-August 1): Are The Others In Your Portfolio? ↗

August 03, 2025

Ten large-cap stocks, including Novo Nordisk and UPS, tumbled last week on weak earnings and guidance cuts.

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

August 01, 2025

From Pomerantz LLP

Via GlobeNewswire

EXELIXIS INC (NASDAQ:EXEL): A Strong Value Investment with Undervalued Potential and Solid Fundamentals ↗

July 30, 2025

EXELIXIS (EXEL) is a top value stock with strong fundamentals—undervalued P/E, zero debt, high profitability, and solid growth. Ideal for value investors seeking quality at a discount.

Via Chartmill

Assessing Exelixis: Insights From 20 Financial Analysts ↗

July 29, 2025

Via Benzinga

Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plans ↗

July 29, 2025

Exelixis Q2 revenue missed estimates, but strong Cabometyx sales lifted earnings. STELLAR trial delays and strategy shifts shaped the update.

Via Benzinga

AMD Rises To 1-Year Highs, Crude Eyes $68: What's Moving Markets Tuesday? ↗

July 29, 2025

Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record highs as investors braced for a pivotal stretch of earnings and macro events.

Via Benzinga

Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

July 29, 2025

Via Benzinga

Exelixis Q2 Revenue Falls 11 Percent ↗

July 28, 2025

Via The Motley Fool

Topics Earnings Intellectual Property

12 Health Care Stocks Moving In Monday's After-Market Session ↗

July 28, 2025

Via Benzinga

Curious about the stocks that are showing activity after the closing bell on Monday? ↗

July 28, 2025

After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Via Chartmill

Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update

July 28, 2025

From Exelixis, Inc.

Via Business Wire

EXELIXIS INC (NASDAQ:EXEL): A Prime Example of Affordable Growth in Biotech ↗

July 28, 2025

EXELIXIS (NASDAQ:EXEL) offers strong growth, fair valuation, and financial health, fitting the "Affordable Growth" strategy with high scores in profitability and low bankruptcy risk.

Via Chartmill

Topics Bankruptcy

Earnings Scheduled For July 28, 2025 ↗

July 28, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.